173 related articles for article (PubMed ID: 20100207)
1. Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G arrest induction.
Horie K; Tsuchihara M; Nakatsura T
Cancer Sci; 2010 Apr; 101(4):913-9. PubMed ID: 20100207
[TBL] [Abstract][Full Text] [Related]
2. The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression.
Fenouille N; Robert G; Tichet M; Puissant A; Dufies M; Rocchi S; Ortonne JP; Deckert M; Ballotti R; Tartare-Deckert S
Pigment Cell Melanoma Res; 2011 Feb; 24(1):219-32. PubMed ID: 20955243
[TBL] [Abstract][Full Text] [Related]
3. SPARC is expressed in human uveal melanoma and its abrogation reduces tumor cell proliferation.
Maloney SC; Marshall JC; Antecka E; Orellana ME; Fernandes BF; Martins C; Castiglione E; DI Cesare S; Logan P; Burnier MN
Anticancer Res; 2009 Aug; 29(8):3059-64. PubMed ID: 19661316
[TBL] [Abstract][Full Text] [Related]
4. Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity.
Alvarez MJ; Prada F; Salvatierra E; Bravo AI; Lutzky VP; Carbone C; Pitossi FJ; Chuluyan HE; Podhajcer OL
Cancer Res; 2005 Jun; 65(12):5123-32. PubMed ID: 15958556
[TBL] [Abstract][Full Text] [Related]
5. Loss of insulin-like growth factor I receptor-dependent expression of p107 and cyclin A in cells that lack the extracellular matrix protein secreted protein acidic and rich in cysteine.
Basu A; Rodeck U; Prendergast GC; Howe CC
Cell Growth Differ; 1999 Nov; 10(11):721-8. PubMed ID: 10593648
[TBL] [Abstract][Full Text] [Related]
6. Preconditioned endothelial progenitor cells reduce formation of melanoma metastases through SPARC-driven cell-cell interactions and endocytosis.
Defresne F; Bouzin C; Grandjean M; Dieu M; Raes M; Hatzopoulos AK; Kupatt C; Feron O
Cancer Res; 2011 Jul; 71(14):4748-57. PubMed ID: 21616936
[TBL] [Abstract][Full Text] [Related]
7. Proteomic analysis identified N-cadherin, clusterin, and HSP27 as mediators of SPARC (secreted protein, acidic and rich in cysteines) activity in melanoma cells.
Sosa MS; Girotti MR; Salvatierra E; Prada F; de Olmo JA; Gallango SJ; Albar JP; Podhajcer OL; Llera AS
Proteomics; 2007 Nov; 7(22):4123-34. PubMed ID: 17994631
[TBL] [Abstract][Full Text] [Related]
8. SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth.
Prada F; Benedetti LG; Bravo AI; Alvarez MJ; Carbone C; Podhajcer OL
J Invest Dermatol; 2007 Nov; 127(11):2618-28. PubMed ID: 17625595
[TBL] [Abstract][Full Text] [Related]
9. PAX4 has the potential to function as a tumor suppressor in human melanoma.
Hata S; Hamada J; Maeda K; Murai T; Tada M; Furukawa H; Tsutsumida A; Saito A; Yamamoto Y; Moriuchi T
Int J Oncol; 2008 Nov; 33(5):1065-71. PubMed ID: 18949370
[TBL] [Abstract][Full Text] [Related]
10. Silencing livin gene by siRNA leads to apoptosis induction, cell cycle arrest, and proliferation inhibition in malignant melanoma LiBr cells.
Wang H; Tan SS; Wang XY; Liu DH; Yu CS; Bai ZL; He DL; Zhao J
Acta Pharmacol Sin; 2007 Dec; 28(12):1968-74. PubMed ID: 18031611
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of secreted protein acidic and rich in cysteine (SPARC) expression diminishes radiosensitivity of glioma cells.
Liu H; Zhang H; Jiang X; Ma Y; Xu Y; Feng S; Liu F
Cancer Biother Radiopharm; 2011 Dec; 26(6):705-15. PubMed ID: 22145659
[TBL] [Abstract][Full Text] [Related]
12. Unraveling mysteries of the multifunctional protein SPARC.
Fukunaga-Kalabis M; Herlyn M
J Invest Dermatol; 2007 Nov; 127(11):2497-8. PubMed ID: 17934501
[TBL] [Abstract][Full Text] [Related]
13. Small interfering RNA inhibition of SPARC attenuates the profibrotic effect of transforming growth factor beta1 in cultured normal human fibroblasts.
Zhou X; Tan FK; Guo X; Wallis D; Milewicz DM; Xue S; Arnett FC
Arthritis Rheum; 2005 Jan; 52(1):257-61. PubMed ID: 15641096
[TBL] [Abstract][Full Text] [Related]
14. NADPH oxidase 4 contributes to transformation phenotype of melanoma cells by regulating G2-M cell cycle progression.
Yamaura M; Mitsushita J; Furuta S; Kiniwa Y; Ashida A; Goto Y; Shang WH; Kubodera M; Kato M; Takata M; Saida T; Kamata T
Cancer Res; 2009 Mar; 69(6):2647-54. PubMed ID: 19276355
[TBL] [Abstract][Full Text] [Related]
15. Polyamine depletion in human melanoma cells leads to G1 arrest associated with induction of p21WAF1/CIP1/SDI1, changes in the expression of p21-regulated genes, and a senescence-like phenotype.
Kramer DL; Chang BD; Chen Y; Diegelman P; Alm K; Black AR; Roninson IB; Porter CW
Cancer Res; 2001 Nov; 61(21):7754-62. PubMed ID: 11691789
[TBL] [Abstract][Full Text] [Related]
16. SPARC regulates cell cycle progression in mesangial cells via its inhibition of IGF-dependent signaling.
Francki A; Motamed K; McClure TD; Kaya M; Murri C; Blake DJ; Carbon JG; Sage EH
J Cell Biochem; 2003 Mar; 88(4):802-11. PubMed ID: 12577314
[TBL] [Abstract][Full Text] [Related]
17. [The role of SPARC gene in tumorigenic capacity of human melanoma cells].
Ledda MF; Adris S; Bover L; Bravo AL; Mordoh J; Podhajcer OL
Medicina (B Aires); 1996; 56(1):51-4. PubMed ID: 8734932
[TBL] [Abstract][Full Text] [Related]
18. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential.
Huang S; Luca M; Gutman M; McConkey DJ; Langley KE; Lyman SD; Bar-Eli M
Oncogene; 1996 Dec; 13(11):2339-47. PubMed ID: 8957075
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach.
Tao J; Tu YT; Huang CZ; Feng AP; Wu Q; Lian YJ; Zhang LX; Zhang XP; Shen GX
Br J Dermatol; 2005 Oct; 153(4):715-24. PubMed ID: 16181451
[TBL] [Abstract][Full Text] [Related]
20. Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells.
Sturm RA; Satyamoorthy K; Meier F; Gardiner BB; Smit DJ; Vaidya B; Herlyn M
Cancer Res; 2002 Jan; 62(1):226-32. PubMed ID: 11782382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
